Serum Myostatin and Irisin Levels in Postmenopausal Women: Association With Bone Mineral Density and Muscle Strength
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Osteoporosis, Osteopenia. Basic parameters: 50 years — 65 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of the Relationship Between Serum Myostatin and Irisin Levels and Bone Mineral Density and Muscle Strength in Postmenopausal Women
Overview
This study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women. Participants will be grouped according to bone mineral density as normal, osteopenic, or osteoporotic. Serum myostatin and irisin levels will be measured, and muscle strength will be assessed using handgrip strength and the five times sit-to-stand test. The associations between biochemical and functional parameters will be analyzed.
Detailed description
This cross-sectional observational study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women. Postmenopausal women aged between 50 and 65 years who meet the inclusion criteria will be enrolled in the study. Bone mineral density will be assessed using dual-energy X-ray absorptiometry (DEXA), and participants will be classified into three groups as normal, osteopenic, or osteoporotic according to T-scores.
Serum myostatin and irisin levels will be measured from venous blood samples collected after overnight fasting. Muscle strength will be evaluated using handgrip strength, and functional performance will be assessed with the five times sit-to-stand test. Demographic and clinical characteristics of the participants will also be recorded.
The relationships between serum myostatin and irisin levels and bone mineral density and muscle strength parameters will be analyzed using appropriate statistical methods.
Primary outcome measures
- Relationship between serum myostatin and irisin levels and bone mineral density (T-score) [Time frame: Baseline]
Secondary outcome measures (2)
- Relationship between serum myostatin and irisin levels and muscle strength [Time frame: Baseline]
- Comparison of serum myostatin and irisin levels among bone mineral density groups [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Postmenopausal women aged between 50 and 65 years Availability of bone mineral density measurement by dual-energy X-ray absorptiometry (DEXA) Willingness to participate in the study
Exclusion criteria
- Presence of malignancy Chronic kidney disease Chronic liver disease Neuromuscular disorders Recent major surgery or trauma Use of medications affecting bone or muscle metabolism
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-only
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07519551 · MYO-IRISIN-BMD-2026-01